Patients with muscle-invasive bladder cancer who underwent whole pelvis radiation showed improved cancer-specific survival and overall survival.

With the FDA's acceptance of Urogen's NDA and issuance of an 06/13/2025 PDUFA the clock is now ticking for FDA approval of ...

Bladder cancer is the ninth most common cancer worldwide, and the number of diagnosed incident cases is set to increase.

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting - IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, ...

The FDA is currently evaluating the application of intravesical mitomycin for low-grade intermediate-risk non–muscle-invasive bladder cancer.

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

In a phase 1b trial, treatment of patients with muscle-invasive bladder cancer with intravesical oncolytic virus cretostimogene grenadenorepvec in combination with nivolumab was safe and led to ...

Research and development expenses for the third quarter of 2024 increased to $8.1 million from $6.2 million for the prior ...

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc. (CGON – Research Report). The associated ...